Actual Medicinal Product (AMP) Arythmol 150mg tablets (Mawdsley-Brooks & Company Ltd)

Stability Information

(Some stability information inherited from generic)

Stability
compatible_special_measures logo There are concerns about stability and/or there is a lack of stability data available. These medicines can theoretically be used in MCAs, although use is likely to be off-label.  Mitigation measures may need to be considered.  Keep medicines in MCAs for the shortest time necessary.  Generally, up to 5 weeks maximum unless otherwise specified, or consider up to 8 weeks if the MCA is airtight (sealed). Consider the risk to the individual from potency loss or dose variability, particularly with unsealed devices. Monitor for any changes in therapeutic effect or increased adverse effects after MCA initiation.
Notes

Protect from light and store in airtight containers.

Provenance

This compatibility recommendation is derived from Arythmol 150mg and 300mg tablets (Viatris UK Healthcare Ltd).

Generic
Propafenone
Formulation
Propafenone 150mg tablets
  • Propafenone
    • Propafenone 150mg tablets

      • Arythmol 150mg tablets (Mawdsley-Brooks & Company Ltd)